News und Analysen
Acadia Healthcare Announces Date for Second Quarter 2023 Earnings Release
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that it will release its second quarter 2023 results on Thursday, July 27, 2023, after the close of the market. Acadia will conduct a
Dexcom Schedules Second Quarter 2023 Earnings Release and Conference Call for July 27, 2023 at 4:30 p.m. Eastern Time
DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2023 financial results after market close on Thursday, July 27, 2023. Management will hold a conference call
Novocure to Report Second Quarter 2023 Financial Results
Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2023 on Thursday, July 27, 2023, before the U.S. financial markets open. Novocure management
Agilent Innovation Again Recognized with Multiple Scientists' Choice Awards
Agilent Technologies Inc. (NYSE: A) has announced the receipt of three 2023 Scientists’ Choice Awards; Best New Spectroscopy Product of 2022, Analytical Science Video of the Year, Analytical
NanoString Reports Inducement Grants Under Nasdaq Listing Rules
NanoString Technologies, Inc. (Nasdaq: NSTG), a leading provider of life science tools for discovery and translational research, today announced, as required by Nasdaq Stock Market Rules, equity
Acadia Healthcare Forms Joint Venture Partnership with SolutionHealth in New Hampshire
Acadia Healthcare Company, Inc. (NASDAQ: ACHC) announced today that it has formed a joint venture with SolutionHealth to build a modern 144-bed behavioral health hospital in southeast New Hampshire
SolutionHealth and Acadia Healthcare Form Joint Venture to Build a Behavioral Health Hospital in Southeast New Hampshire
The Board of Trustees of SolutionHealth, parent organization of Elliot Health System and Southern New Hampshire Health, has formed a joint venture with Acadia Healthcare, a leading provider of
Navidea Biopharmaceuticals, Inc. Rejects Unsolicited Offer To Acquire Certain Assets
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, and Voyager Therapeutics, Inc. (Nasdaq: VYGR), today announced the parties have entered into a definitive license agreement
Vistagen Provides Corporate Update and Reports Fiscal Year 2023 Financial Results
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
CenterWell Home Health regions recognized by American Diabetes Association for delivery of diabetes self-management education and support
Two of CenterWell Home Health’s four regions have been recognized by the American Diabetes Association (ADA) for delivering the best in self-management education and support for people with
FDA Approves Pfizer’s NGENLA™, a Long-Acting Once-Weekly Treatment for Pediatric Growth Hormone Deficiency
Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) has approved NGENLA (somatrogon-ghla), a once-weekly, human growth
Vistagen to Announce Fiscal Year 2023 Financial Results and Provide Corporate Update Conference Call on June 28, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
FDA Accepts Pfizer’s Application for Hemophilia B Gene Therapy Fidanacogene Elaparvovec
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) for fidanacogene elaparvovec for the
Savara Added to Russell 3000® Index
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has been added to the U.S. broad-market Russell 3000® Index at
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that enrollment has been completed for the pivotal Phase 3 IMPALA-2
Pfizer Provides Update on GLP-1-RA Clinical Development Program for Adults with Obesity and Type 2 Diabetes Mellitus
Pfizer Inc. (NYSE: PFE) today announced its decision to continue to progress one oral late-stage glucagon-like peptide-1 receptor agonist (GLP-1-RA) candidate toward further clinical development
Global Continuous Glucose Monitoring Pioneer Dexcom Reveals New Plans to Bring Sensing Technology to Millions More
Dexcom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people living with diabetes, announced today its strategy to bring Dexcom glucose sensing
Dexcom Updates Long-Range Financial Targets
DexCom, Inc. (NASDAQ:DXCM) today announced an update to its long-range financial targets at its 2023 Investor Day. Based on the company’s strong performance in the first two years of the target
FDA Approves Pfizer’s LITFULO™ (Ritlecitinib) for Adults and Adolescents With Severe Alopecia Areata
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved LITFULO™ (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older
Vistagen Regains Full Compliance with Nasdaq Listing Requirements
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Premier, Inc. Honors Program that Helps Low-Income Seniors Age in Place with National Award and $100,000 Donation
Aging Gracefully, a nonprofit program dedicated to making homes safer for low-income adults over the age of 65, has received the 2023 Premier Cares Award and a $100,000 cash prize from Premier,
Pfizer Declares Third-Quarter 2023 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 third-quarter 2023 dividend on the company’s common stock, payable September 5, 2023, to holders of the Common
Owens & Minor to Participate in UBS Healthcare Services Conference on Tuesday, June 27, 2023
Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that incorporates product manufacturing, distribution support and innovative technology services, announced today that Ed
Simulations Plus Announces Third Quarter Fiscal Year 2023 Earnings and Conference Call Date
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2023 financial results after the market close on Thursday, July 6, 2023.